These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 7889289

  • 1. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
    Lucchessi BR, Rote WE, Driscoll EM, Mu DX.
    Br J Pharmacol; 1994 Dec; 113(4):1333-43. PubMed ID: 7889289
    [Abstract] [Full Text] [Related]

  • 2. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA, Forsythe MS, Diemer M, Bozarth JM, Reilly TM.
    Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
    [Abstract] [Full Text] [Related]

  • 3. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 4. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs.
    Mousa SA, Mu DX, Lucchesi BR.
    Stroke; 1997 Apr; 28(4):830-5; discussion 835-6. PubMed ID: 9099204
    [Abstract] [Full Text] [Related]

  • 5. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 6. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery.
    Rote WE, Werns SW, Davis JH, Feigen LP, Kilgore KS, Lucchesi BR.
    Cardiovasc Res; 1993 Mar; 27(3):500-7. PubMed ID: 8490951
    [Abstract] [Full Text] [Related]

  • 7. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR.
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [Abstract] [Full Text] [Related]

  • 8. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
    [Abstract] [Full Text] [Related]

  • 9. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis.
    Rote WE, Davis JH, Mousa SA, Reilly TM, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):681-9. PubMed ID: 7516023
    [Abstract] [Full Text] [Related]

  • 11. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ.
    J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
    [Abstract] [Full Text] [Related]

  • 12. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK.
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [Abstract] [Full Text] [Related]

  • 13. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS.
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [Abstract] [Full Text] [Related]

  • 14. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
    Rebello SS, Driscoll EM, Lucchesi BR.
    Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027
    [Abstract] [Full Text] [Related]

  • 15. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE, Abendschein DR.
    Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
    [Abstract] [Full Text] [Related]

  • 16. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis.
    Sudo Y, Kilgore KS, Lucchesi BR.
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):241-50. PubMed ID: 7475049
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
    Willette RN, Sauermelch CF, Rycyna R, Sarkar S, Feuerstein GZ, Nichols AJ, Ohlstein EH.
    Stroke; 1992 May; 23(5):703-11. PubMed ID: 1605806
    [Abstract] [Full Text] [Related]

  • 20. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.